These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44 related articles for article (PubMed ID: 28244737)
1. Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies. Andrade EL; Bento AF; Cavalli J; Oliveira SK; Freitas CS; Marcon R; Schwanke RC; Siqueira JM; Calixto JB Braz J Med Biol Res; 2016 Oct; 49(11):e5644. PubMed ID: 27783811 [TBL] [Abstract][Full Text] [Related]
2. The Synthesis and Antibacterial Properties of Pillar[5]arene with Streptocide Fragments. Subakaeva E; Zelenikhin P; Sokolova E; Pergat A; Aleksandrova Y; Shurpik D; Stoikov I Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140001 [TBL] [Abstract][Full Text] [Related]
3. Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands. Sun J; Zhong H; Wang K; Li N; Chen L Acta Pharm Sin B; 2021 Nov; 11(11):3417-3432. PubMed ID: 34900527 [TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19). Verma S; Twilley D; Esmear T; Oosthuizen CB; Reid AM; Nel M; Lall N Front Pharmacol; 2020; 11():561334. PubMed ID: 33101023 [TBL] [Abstract][Full Text] [Related]
5. The Ecstasy and Agony of Assay Interference Compounds. Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S ACS Chem Biol; 2017 Mar; 12(3):575-578. PubMed ID: 28244728 [No Abstract] [Full Text] [Related]
6. The Ecstasy and Agony of Assay Interference Compounds. Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S J Med Chem; 2017 Mar; 60(6):2165-2168. PubMed ID: 28244745 [No Abstract] [Full Text] [Related]
7. The Ecstasy and Agony of Assay Interference Compounds. Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S J Chem Inf Model; 2017 Mar; 57(3):387-390. PubMed ID: 28244743 [No Abstract] [Full Text] [Related]
8. The Ecstasy and Agony of Assay Interference Compounds. Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S Biochemistry; 2017 Mar; 56(10):1363-1366. PubMed ID: 28244742 [No Abstract] [Full Text] [Related]
9. The Ecstasy and Agony of Assay Interference Compounds. Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S ACS Infect Dis; 2017 Apr; 3(4):259-262. PubMed ID: 28244723 [No Abstract] [Full Text] [Related]
10. The Ecstasy and Agony of Assay Interference Compounds. Aldrich C; Bertozzi C; Georg GI; Kiessling L; Lindsley C; Liotta D; Merz KM; Schepartz A; Wang S ACS Chem Neurosci; 2017 Mar; 8(3):420-423. PubMed ID: 28244737 [No Abstract] [Full Text] [Related]
11. Comment on The Ecstasy and Agony of Assay Interference Compounds. Kenny PW J Chem Inf Model; 2017 Nov; 57(11):2640-2645. PubMed ID: 29048168 [TBL] [Abstract][Full Text] [Related]
12. Frequent hitters: nuisance artifacts in high-throughput screening. Yang ZY; He JH; Lu AP; Hou TJ; Cao DS Drug Discov Today; 2020 Apr; 25(4):657-667. PubMed ID: 31987936 [TBL] [Abstract][Full Text] [Related]